Trials / Completed
CompletedNCT02013544
Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 558 (actual)
- Sponsor
- EndoCeutics Inc. · Industry
- Sex
- Female
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to confirm the efficacy of intravaginal prasterone (DHEA) on symptoms of vulvovaginal atrophy due to menopause and to collect further data on subjects exposed to intravaginal DHEA in order to meet the ICH E1 guideline requirements.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | |
| DRUG | Prasterone (DHEA) |
Timeline
- Start date
- 2014-02-01
- Primary completion
- 2015-01-01
- Completion
- 2015-02-01
- First posted
- 2013-12-17
- Last updated
- 2017-06-01
- Results posted
- 2017-06-01
Locations
38 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT02013544. Inclusion in this directory is not an endorsement.